



The CRISPR-Cas Mechanism for Adaptive Immunity and Alternate Bacterial Functions Fuels Diverse Biotechnologies

OPEN ACCESS

Edited by:

Erika Ildiko Lutter,
Oklahoma State University,
United States

Reviewed by:

Karine Dufresne,
University of Western Ontario, Canada
Vikas Yadav,
Duke University, United States
Pragyesh Dhungel,
Sandia National Laboratories (SNL),
United States

*Correspondence:

Rakhi Rajan
r-rajan@ou.edu

[†]These authors have contributed
equally to this work

Specialty section:

This article was submitted to
Molecular Bacterial Pathogenesis,
a section of the journal
Frontiers in Cellular and
Infection Microbiology

Received: 21 October 2020

Accepted: 14 December 2020

Published: 28 January 2021

Citation:

Newsom S, Parameshwaran HP,
Martin L and Rajan R (2021) The
CRISPR-Cas Mechanism
for Adaptive Immunity and
Alternate Bacterial Functions
Fuels Diverse Biotechnologies.
Front. Cell. Infect. Microbiol. 10:619763.
doi: 10.3389/fcimb.2020.619763

Sydney Newsom[†], Hari Priya Parameshwaran[†], Lindsie Martin[†] and Rakhi Rajan^{*}

Department of Chemistry and Biochemistry, Price Family Foundation Structural Biology Center, Stephenson Life Sciences
Research Center, University of Oklahoma, Norman, OK, United States

Bacterial and archaeal CRISPR-Cas systems offer adaptive immune protection against foreign mobile genetic elements (MGEs). This function is regulated by sequence specific binding of CRISPR RNA (crRNA) to target DNA/RNA, with an additional requirement of a flanking DNA motif called the protospacer adjacent motif (PAM) in certain CRISPR systems. In this review, we discuss how the same fundamental mechanism of RNA-DNA and/or RNA-RNA complementarity is utilized by bacteria to regulate two distinct functions: to ward off intruding genetic materials and to modulate diverse physiological functions. The best documented examples of alternate functions are bacterial virulence, biofilm formation, adherence, programmed cell death, and quorum sensing. While extensive complementarity between the crRNA and the targeted DNA and/or RNA seems to constitute an efficient phage protection system, partial complementarity seems to be the key for several of the characterized alternate functions. Cas proteins are also involved in sequence-specific and non-specific RNA cleavage and control of transcriptional regulator expression, the mechanisms of which are still elusive. Over the past decade, the mechanisms of RNA-guided targeting and auxiliary functions of several Cas proteins have been transformed into powerful gene editing and biotechnological tools. We provide a synopsis of CRISPR technologies in this review. Even with the abundant mechanistic insights and biotechnology tools that are currently available, the discovery of new and diverse CRISPR types holds promise for future technological innovations, which will pave the way for precision genome medicine.

Keywords: clustered regularly interspaced short palindromic repeats and clustered regularly interspaced short palindromic repeat-associated (CRISPR-Cas), adaptive immunity, Cas9, cascade, gene editing, bacterial pathogenesis, gene regulation, Cas12a

INTRODUCTION

Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) and CRISPR-associated (Cas) proteins constitute an RNA-guided adaptive immune system found in several bacteria and most archaea. Over the past decade, detailed molecular mechanisms were discovered which established CRISPR-Cas not just as a phage defense system, but also as a regulator of bacterial physiology such as virulence and group behaviors. (Murugan et al., 2017; Faure et al., 2019; Liu and Doudna, 2020). In this review, we cover the roles of CRISPR-Cas systems within and outside the realm of adaptive immunity and detail the repertoire of biotechnological tools developed from them.

CRISPR-CAS IN IMMUNITY

Discovery of CRISPR-Cas

CRISPR was discovered over 30 years ago in *Escherichia coli* and later in archaea (Ishino et al., 1987; Mojica et al., 1993). Cas proteins were originally thought to perform DNA repair (Makarova et al., 2002), but were later found to be associated with CRISPR (Jansen et al., 2002). The discovery that spacer sequences match foreign genetic elements led to the hypothesis that CRISPR-Cas is an immune system to protect against invading mobile genetic elements (Bolotin et al., 2005; Mojica et al., 2005; Makarova et al., 2006). Experimental validation of RNA-guided DNA cleavage protecting against intruding phages established CRISPR-Cas as an adaptive immune system (Barrangou et al., 2007).

Classification of CRISPR-Cas Systems

In CRISPR-Cas, the RNA-guided DNA/RNA cleavage occurs through an “effector complex” composed of an RNA guide called CRISPR RNA (crRNA) and a set of Cas proteins (Class 1) or a single multi-domain Cas protein (Class 2) (Figure 1A). The two classes are each divided into three types, based on the identity of the signature protein that cleaves the target nucleic acid, and further into several subtypes based on the CRISPR-Cas locus

architecture. The most updated classification has 2 classes, 6 types and 33 subtypes (Makarova et al., 2020).

Class 1 CRISPR-Cas systems are most abundant and include types I, III, and IV (Figure 1A, Makarova et al., 2015; Makarova et al., 2020). The type I effector complex is called CASCADE (CRISPR-associated complex for antiviral defense), which comprises crRNA and multiple Cas proteins (Brouns et al., 2008; Jore et al., 2011). Once CASCADE locates the target DNA, Cas3 is recruited for DNA cleavage (Sinkunas et al., 2011). The nuclease and helicase activities of Cas3 bring about long-range degradation of intruder DNA (Huo et al., 2014). Type III is unique since it targets and cleaves transcriptionally active RNA using crRNA complementarity, which in turn activates cleavage of the ssDNA associated with the transcription bubble. While Cas7 cleaves the RNA, Cas10 cleaves the ssDNA (Taylor et al., 2015; Mogila et al., 2019; You et al., 2019). Both these activities are essential for full immune protection, with certain systems collaborating with degradosome-nucleases for efficient clearing of intruder nucleic acids (Staals et al., 2013; Staals et al., 2014; Samai et al., 2015; Estrella et al., 2016; Kazlauskienė et al., 2016; Chou-Zheng and Hatoum-Aslan, 2019). Type IV is a minimalistic CRISPR-Cas system devoid of adaptation proteins, mostly found in plasmids or plasmid-like regions and may be involved in plasmid maintenance (Makarova et al., 2020). DinG helicase is essential for plasmid interference in type IV-A, but the nuclease identity is currently unknown (Crowley et al., 2019; Özcan et al., 2019; Pinilla-Redondo et al., 2020).

Class 2 CRISPR-Cas systems consist of types II, V and VI (Figure 1A). The type II effector protein Cas9 introduces dsDNA breaks in target DNA using HNH and RuvC endonucleases. Type II systems need an accessory non-coding RNA, *trans*-activating crRNA (tracrRNA), along with crRNA for DNA cleavage (Jinek et al., 2012). Type V systems have Cas12 as the signature effector protein and causes staggered, sequence-specific DNA cleavage using RuvC domain. Subtype-specific variation of the target (DNA vs. RNA) and guide RNA requirements [crRNA or crRNA-tracrRNA or crRNA-scout (short-complementarity untranslated)] have also been observed in type V systems (Zetsche et al., 2015, 1; Yan et al., 2019; Harrington et al., 2020). The type VI signature nuclease, Cas13, binds crRNA and locates a complementary RNA target, followed by processive RNase activity using HEPN domains (Abudayyeh et al., 2016; O’Connell, 2019).

Stages in CRISPR-Cas Defense

There are three distinct stages for CRISPR defense.

- (1) **Adaptation:** During adaptation, a short DNA is excised from intruding DNA and inserted site-specifically into the CRISPR array, creating a new spacer. Known adaptation mechanisms require Cas1 and Cas2 to capture and catalytically insert the spacer. Auxiliary proteins like Cas4, Csn2, Cas9, or non-Cas proteins such as integration host factor are essential for fidelity in certain subtypes. Type III systems with reverse transcriptase-Cas1 fusion proteins can acquire spacers from RNA (Silas et al., 2016). Details of adaptation have been recently reviewed (Sternberg et al., 2016; Mosterd et al., 2020).

Abbreviations: BLP, bacterial lipoprotein; Cas, CRISPR-associated; cOA, cyclic oligo-adenylate; CovR/S, control of virulence regulator and sensor; CRISPR, clustered, regularly interspaced short palindromic repeats; crRNA, CRISPR RNA; dCas, nuclease inactivated dead Cas protein; ds, double stranded; FasA/FasB, fibronectin/fibrinogen-binding/hemolytic activity/streptokinase regulatory (Fas) system; HD, histidine and aspartate; HDR, homology directed repair; HEPN, higher eukaryotes and prokaryotes nucleotide-binding; HGT, horizontal gene transfer; LasR, acyl-homoserine-lactone quorum sensing circuit regulator; LsrF, 3-hydroxy-5-phosphonooxypentane-2,4-dione thiolase; Mga, multigene regulator in GAS; NHEJ, non-homologous end joining; PCD, programmed cell death; QS, quorum sensing; scaRNA, small, CRISPR-Cas-associated RNA; ScpA, streptococcal C5a peptidase; sgRNA, single guide RNA; SIC, streptococcal inhibitor of complement; SpyCas9, *Streptococcus pyogenes* Cas9; ss, single stranded; TALENS, Transcription activator-like effector nucleases; TCS, two-component system; TLR, toll-like receptor; tracrRNA, *trans*-activating crRNA; VicR/K, a TCS with a putative histidine kinase (VicK) and a response regulator (VicR).




FIGURE 1 | Clustered Regularly Interspaced Short Palindromic Repeats and CRISPR-associated (CRISPR-Cas) classification, interference complexes, and alternate functions. **(A)** Interference complexes, crRNA maturation, and nucleic acid targeting. Type I-E CASCADE from *Escherichia coli* is shown. The interference complex comprises six Cas7s, two Cas11s, and one each of Cas5, Cas8, and Cas6. This complex recruits Cas3, which uses a histidine aspartate (HD) nuclease domain to nick the target DNA, followed by unwinding of the DNA by helicase domain and long-range degradation of DNA by the HD domain. Type III is an RNA-targeting system with a historical distinction into two groups of effector complexes, “Csm” (Cas subtype MtuB, includes subtypes A, D, E and F) and “Cmr” (Cas module RAMP, includes subtypes B and C), differentiated based on the sequences of Cas11 subunit, called as Csm2 and Cmr5 respectively in Csm and Cmr complexes (Tamulaitis et al., 2017). Type III-B from *Pyrococcus furiosus* is shown. The interference complex comprises six Cas7s, coded by three distinct genes (*cmr4*, *cmr1* and *cmr6*), three Cas11s, and one each of Cas5 and Cas10. While Cas7 cleaves target RNA with a 6-nucleotide periodicity, Cas10 cleaves ssDNA in the transcription bubble using its HD domain. The Palm domain of Cas10 produces cyclic oligo-adenylate (cOA) that activates Csx1 for non-specific RNA cleavage. Type IV is represented by subtype A1 from *Aromatobacterium aromaticum*. The interference complex comprises Cas5, Cas6, Cas8, and multiple Cas7s, although the exact subunit stoichiometry is unknown. DinG is a helicase necessary for interference. Question marks and arrows in type IV-A1 indicate that subunit organization and nuclease identity is unknown. Cas6, the protein required for crRNA processing may or may not be part of the effector complex in Class I systems. Each class II system is represented by its respective subtype A. Type II-A Cas9 uses its HNH endonuclease domain to cleave the DNA strand hybridized to crRNA and RuvC endonuclease domain to cleave the other strand. RNaseIII is required for crRNA processing in type II systems. Type V-A Cas12a (previously called Cpf1) uses RuvC domain to cleave both strands of the target DNA, even though assistance of the Nuc domain is needed to cleave the strand hybridized to crRNA. Cas12a also possesses non-specific DNA cleavage, called trans-cleavage. Type VI-A Cas13a uses two higher eukaryotes and prokaryotes nucleotide-binding (HEPN) domains to elicit sequence-specific and collateral (non-specific) cleavage of target RNA. Type V-A and type VI systems possess specific sites within their effector protein for crRNA processing. Secondary trimming for crRNA maturation is not shown. Protein legacy names are given in parentheses. PAM stands for protospacer adjacent motif, PFS stands for protospacer flanking site, and 3' flank stands for 3' flanking sequence of the protospacer that is non-complementary to the 5'-tag of crRNA; each of which are used for self vs. non-self recognition. Nucleic acids are not to scale with proteins. Target or non-specifically cleaved RNA is in purple, crRNA is red, tracrRNA is in black and DNA is blue. **(B)** Left: *Pseudomonas aeruginosa* (type I-F) Cas3-mediated RNA and DNA targeting affect host immune evasion and biofilm formation respectively. Right: Comparison between *Streptococcus agalactiae* (type II-A) and *Francisella novicida* (type II-B) mechanisms of Cas9-mediated down-regulation of endogenous genes. The differences include the type of guide RNA (crRNA vs. scaRNA), nucleic acid target (mRNA vs. genomic DNA), mode of repression (transcript degradation vs. steric hindrance to RNA-polymerase), and endogenous gene target (master regulatory protein vs. regulon affecting virulence). Created with BioRender.com.

- (2) **crRNA Processing:** Typically, the CRISPR array is transcribed into a long pre-crRNA, which associates with Cas proteins for further processing into mature crRNAs. Class 1 systems require Cas6 to process pre-crRNA into individual crRNA molecules (Figure 1A, (Staals et al., 2013; Staals et al., 2014; Taylor et al., 2019)). Class 2 systems do not possess a signature Cas protein for crRNA processing, but rather use distinct mechanisms: type II systems depend on RNase III (Deltcheva et al., 2011; Charpentier et al., 2015), type V-A and type VI signature nucleases possess a distinct active site for crRNA processing, and certain type V subtypes depend on host nucleases (East-Seletsky et al., 2016; Fonfara et al., 2016; Liu et al., 2017). Certain type-II systems directly transcribe mature crRNAs using individual promoters within the CRISPR array (Zhang et al., 2013).
- (3) **Interference:** This stage involves the sequence-specific targeting and cleavage of foreign DNA and/or RNA. The classification section above details relevant proteins and cleavage types. Structural and mechanistic details of CRISPR interference have been recently reviewed (Murugan et al., 2017; Liu and Doudna, 2020). Interference involves R-loop formation as the crRNA guide-region hybridizes to target DNA or base-pairing between the crRNA guide region and target RNA. This is followed by cleavage/degradation of the target.

CRISPR-Cas systems must distinguish between self and foreign DNA to avoid self-targeting. The characteristics that warrant intruder cleavage are (i) presence of PAM (protospacer adjacent motif), a DNA motif flanking the RNA-DNA complementary region in types I, II, and V; (ii) absence of RNA complementarity between the 5'-tag of crRNA and 3' flank of the target RNA in type III; and (iii) presence of a protospacer flanking sequence (PFS), an RNA motif in the target RNA, in type VI (Gleditsch et al., 2019).

PHYSIOLOGICAL ROLES OF CRISPR-CAS OBSERVED IN BACTERIA

Some bacteria regulate physiological processes using RNA-guided Cas proteins that target the self-genome. While partial complementarity between the guide RNA and the self-genome or endogenous transcripts seems to drive gene regulation, complete complementarity with the genome has been shown to regulate prophage and temperate phage life-cycles and trigger bacterial evolution through recombination to avoid lethal self-targeting (Aklujkar and Lovley, 2010; Vercoe et al., 2013; Goldberg et al., 2014). We review here the roles of CRISPR systems in bacterial pathogenicity and survival.

Virulence

Host Immune Evasion

CRISPR-Cas can regulate gene expression to conceal bacteria from host toll-like receptors (TLR). The best studied example is the *Francisella novicida* U112 type II-B system, which

downregulates a bacterial lipoprotein (BLP) on the cell envelope to evade host immune responses (Sampson et al., 2013; Ratner et al., 2019). This mechanism requires the association of Cas9 with tracrRNA and small, CRISPR-Cas-associated RNA (scaRNA), which specifically represses transcription of a regulon containing *blp* (FTN_1104-1101) (Figure 1B). Transcriptomic studies have revealed similar trends where *blps* are upregulated in *cas9* deletion mutants (Δ cas9) of *Streptococcus agalactiae* GD201008-001 (type II-A) and *Riemerella anatipestifer* (type II-C) (Ma et al., 2018; Wang et al., 2019). In *Streptococcus pyogenes* GAS-MIT1-5448 (type II-A), Δ cas9 produces less master regulator protein Mga, which in turn downregulates *ScpA* and *SIC* proteins, which are essential to inactivate the host complement immune defense (Gao et al., 2019). *S. pyogenes* Cas9 also downregulates the *CovR/S* two component system (TCS) which regulates capsule genes that confer antiphagocytic properties (Sarkar and Sumbly, 2017; Gao et al., 2019). Involvement of a type I-F CRISPR-system in virulence was demonstrated in *Pseudomonas aeruginosa* UCBPP-PA14, where Cas3 degrades the mRNA of the master regulator protein *LasR* to evade the TLR-initiated host immune response (Figure 1B, (Li et al., 2016)). The bacterial molecule regulated to avoid recognition is currently unknown.

Bacterial Adherence and Cytotoxicity

CRISPR-Cas systems modulate bacterial-host interactions, the mechanisms of which are currently evolving. Relative to the wild-type, *Neisseria*, *Streptococcus*, and *Campylobacter* Δ cas9 strains adhere poorly to mammalian host cells (Ma et al., 2018; Shabbir et al., 2018; Heidrich et al., 2019; Spencer et al., 2019; Gao et al., 2019). The *S. pyogenes* mechanism involves Cas9-mediated down-regulation of the *FasA/FasB* TCS that downregulates adhesion factors (Gao et al., 2019). *Campylobacter jejuni* and *S. agalactiae* Cas9s can increase bacterial cytotoxicity, adhesion, and survival within hosts cells (Louwen et al., 2013; Ma et al., 2018; Shabbir et al., 2018; Saha et al., 2020a). In *S. agalactiae*, hyaluronidase activity essential for blood-brain barrier penetration is regulated via Cas9-mediated cleavage of the master regulator *regR* transcript (Figure 1B, (Ma et al., 2018)).

Group Behavior

There is growing evidence that CRISPR systems can regulate group behaviors to increase bacterial virulence. Based on *Salmonella enterica* serovar Enteritidis Δ cas3 (type I-E) transcriptome studies, Cas3 downregulates *LsrF* production, preventing degradation of quorum sensing (QS) signaling molecules by *LsrF*, ultimately increasing expression of the *lsr* QS operon (Cui et al., 2020). Transcriptomic studies of Δ cas3 *Streptococcus mutans* UA159 (type I-C) showed downregulation of biofilm formation genes controlled by the *VicR/K* TCS, which is known to influence streptococcal tissue specificity (Vega et al., 2016; Tang et al., 2019). Phage-dependent biofilm regulation was observed in *Pseudomonas aeruginosa* strain UCBPP-PA14, where partial crRNA hybridization to lysogenized DMS3 phage recruits Cas3 (type I-F) to nick the bacterial genome, initiating a *RecA*-dependent SOS response that inhibits biofilm formation and swarming (Figure 1B, (Heussler et al., 2015)). Experiments

have implicated Cas9-based virulent group behaviors in *C. jejuni* (type II-C) (Shabbir et al., 2018), *S. pyogenes* (type II-A) (Gao et al., 2019), *Neisseria meningitidis* (type II-C) (Sampson et al., 2013), and *S. agalactiae* (type II-A) (Ma et al., 2018) where $\Delta cas9$ strains had decreased biofilm formation.

Relation to Genome Repair and Involvement in Non-Virulent Gene Regulation and Programmed Cell Death

Current research also shows CRISPR-Cas systems regulating genes not directly involved in bacterial virulence. Experimental evidence has demonstrated Cas1's ability to cleave branched DNA substrate and revealed enhanced sensitivity of $\Delta cas1$ *E. coli* to DNA damage (Babu et al., 2011). A recent study has shown that non-homologous end-joining (NHEJ) does not co-exist with type II-A systems due to the competition between Csn2 (type II-A) and NHEJ proteins for DNA substrates. Another DNA-repair system, RecBCD, is essential for spacer acquisition in *E. coli* (type I-E) (Levy et al., 2015). These studies suggest complex interdependence of CRISPR and DNA repair systems, the mechanisms of which are still elusive. Transcriptomic and proteomic studies of $\Delta cas9$ *S. pyogenes* (type II-A) (Gao et al., 2019), Group B *Streptococcus* (type II-A) (Spencer et al., 2019), and *Riemerella anatipestifer* (type II-C) (Wang et al., 2019) have indicated both up- and down- regulation of several endogenous genes, the implications of which are not clear. Several studies in *Myxococcus xanthus* have shown that CRISPR systems are involved in cell-stress dependent sporulation (type I-C) and fruiting body development (type III-B) (Viswanathan et al., 2007; Wallace et al., 2014).

Type III and type VI CRISPR systems promote indiscriminate RNA cleavage leading to PCD, a strategy employed when immune protection has failed (Faure et al., 2019). In type III systems, crRNA binding to target RNA activates production of cyclic oligoadenylate (cOA) by Cas10. The cOA molecules initiate Csm6/Csx1's indiscriminate RNase activity resulting in cell death (Kazlauskienė et al., 2017; Niewoehner et al., 2017). In type VI, crRNA binding to target RNA activates Cas13 for promiscuous RNase activity (Abudayyeh et al., 2016). Interestingly, the resemblance of Cas2 to the toxin component of toxin-antitoxin systems and the genomic co-localization of CRISPR and PCD elements have led to the idea of their co-dependence in bacterial physiology, and are awaiting experimental confirmation (reviewed in Faure et al., 2019).

Diversity of CRISPR-Cas MECHANISMS

Current studies indicate that CRISPR has functions beyond adaptive immunity, primarily in regulating genome content and gene expression. Horizontal Gene Transfer (HGT) can be negatively impacted in CRISPR-containing bacteria since the acquired DNA can be targeted by CRISPR. The effects of CRISPR on HGT are evolving. Some bacteria compensate limitations on HGT by maintaining a defective CRISPR locus or establishing mechanisms for CRISPR-tolerance (Sampson and Weiss, 2013; Wimmer and Beisel, 2020). A different perspective on offsetting this disadvantage has been demonstrated by CRISPR-mediated enhancement of transduction by phages, which then enables

transfer of genetic materials between bacteria (Watson et al., 2018).

Based on studies of streptococcal physiology, we speculate that CRISPR-mediated gene regulation promotes strain differentiation via genome remodeling and regulatory changes. CRISPR changes expression of *S. pyogenes* master regulators Mga and VicR and the TCS CovR/S, which then regulate immunomodulatory virulence factors that drive development of strains with different host tissue preferences and physiologies ranging from hypervirulent to carrier status (Vega et al., 2016; Sarkar and Sumby, 2017). Similarly, natural mutation in *P. aeruginosa* master regulator LasR increases bacterial fitness in the cystic fibrosis lung (Smith et al., 2006). A common theme in these diverse mechanisms is that Cas proteins target genes that bring about differential phenotypes in bacteria. *Legionella pneumophila*'s requirement of Cas2 to infect amoebas indicates the involvement of other Cas proteins in endogenous gene regulation, requiring future studies to unravel more of such mechanisms.

CRISPR-CAS BIOTECHNOLOGY TOOLS

The RNA-guided nucleic acid targeting of Cas proteins offer several biotechnology tools dependent on the diverse CRISPR mechanisms (Table 1). We are providing selected aspects of currently available applications (Table 1), with more details in Table S1 and several recent reviews (Pickar-Oliver and Gersbach, 2019; Xu and Qi, 2019).

Gene Editing

The revolutionary characteristic of CRISPR-Cas-based gene editing is the ability to introduce heritable genome modifications by programming Cas proteins using guide RNAs, instead of modifying the editing protein, which was the limiting aspect of zinc fingers and TALENS (Gaj et al., 2013).

The most widely used CRISPR-based gene editing system is *S. pyogenes* Cas9 (SpyCas9) with a single guide RNA (sgRNA) (Table 1A). The most prominent application is modification of eukaryotic genes utilizing efficient DNA-repair pathways of eukaryotes to repair Cas9 induced DNA breakage by NHEJ (creates gene knock-outs) or homology directed repair (HDR, creates gene knock-ins). An approach to fix genetic mutations while eliminating unwarranted effects from off-target DNA cleavage is fusing Cas9 with base editors (Table 1B, (Komor et al., 2016)). Cas9-based gene editing in prokaryotes is limited due to inefficient DNA repair mechanisms; however, Cas9 cleavage-induced killing of unedited cells can be used to increase efficiency of other bacterial gene-editing methods (Wilson et al., 2003).

Cas12a and CASCADE gene editing systems complement those of Cas9 since their DNA cleavage mechanisms produce HDR-enhancing staggered ends and instill long-range deletions respectively (Dolan et al., 2019; Paul and Montoya, 2020).

Transcript and Epigenetic Manipulation

Transcripts can be targeted and cleaved by Cas13 and some Cas9 orthologs including *Staphylococcus aureus* Cas9 for transcript

TABLE 1 | Clustered Regularly Interspaced Short Palindromic Repeats and CRISPR-associated (CRISPR-Cas) biotechnology applications.

Biotechnology Application	CRISPR-Cas system and relevant activities	References
A. Gene editing	1. SpyCas9 (type II-A) and its high-fidelity variants; light and chemically induced Cas9 expression; sgRNA regulation to control Cas9 2. Cas12a (type V-A), sequence specific DNA cleavage producing staggered ends 3. CASCADE and Cas3 for sequence-specific DNA degradation and Cas8-FokI fusion for sequence-specific DNA cleavage 4. Cmr (type III-B), sequence specific interference of transcriptionally active DNA	1. (Jinek et al., 2012; Cho et al., 2013; Nihongaki et al., 2015; Kleinstiver et al., 2016; Slaymaker et al., 2016; Chen et al., 2017; Maji et al., 2017) 2. (Hur et al., 2016; Yan et al., 2017) 3. (Cameron et al., 2019) 4. (Li et al., 2015)
B. Base editing	SpyCas9 fused to cytidine deaminase or adenosine to inosine deaminase; Cas12a fused to cytidine deaminase; Cas13 fused to adenosine deaminase	(Komor et al., 2016; Cox et al., 2017; Gaudelli et al., 2017; Li et al., 2018)
C. Gene knockdown via ssRNA cleavage	Cas9, Cmr, Cas13-based methods	(Zebec et al., 2014; Abudayyeh et al., 2017; Batra et al., 2017; Konermann et al., 2018; Strutt et al., 2018)
D. Transcriptional repression	Nuclease inactivated SpyCas9 and its tag-fusion derivatives, nuclease inactivated Cas12a, CASCADE without Cas3	(Qi et al., 2013; Rath et al., 2014; Huang et al., 2017; Zhang et al., 2017)
E. Gene activation	Fusions of SpyCas9, Cas12a, and CASCADE to transcriptional activation domains	(Perez-Pinera et al., 2013; Breinig et al., 2019; Young et al., 2019)
F. Nucleic acid detection	Cas12a, Cas13, Csm6	(Gootenberg et al., 2018)

level gene knock-down (Table 1.C, (Konermann et al., 2018; Strutt et al., 2018)). Nuclease inactivated dead Cas (dCas) proteins can block or activate transcription *via* steric hindrance of RNA-polymerase or fusion to transcriptional activators respectively (Table 1.D and E, (Perez-Pinera et al., 2013; Qi et al., 2013)).

Nucleic Acid Detection Kits

Cas12a and Cas13 inherently cleave non-specific nucleic acids after RNA-mediated target binding (Figure 1A), enabling several fluorescent-based detection kits (Table 1.F, (Gootenberg et al., 2018)). Notably, STOP (SHERLOCK Testing in One Pot) for COVID-19 diagnostics (STOPCovid) uses this technology (Joung et al., 2020).

Biomedical Tools and Future Prospects in Genome Medicine

The site-specific genetic modulation facilitated by Cas proteins has been monumental in quickly advancing gene therapy with several ongoing clinical trials for cancer immunotherapies, blood disorders, blindness *etc.* (Table S1.A.6, clinicaltrials.gov). To facilitate progress, SpyCas9 off-targeting concerns are being addressed using highly stringent Cas proteins, temporal control of protein expression, and gene editing reaction activators/quenchers (Table S1.A, (Chen et al., 2017)). As new CRISPR systems with diverse mechanisms are being characterized, new biomedical applications will follow.

OUTLOOK

As described here, CRISPR-Cas is a two-in-one mechanism for protection against intruding nucleic acids as well as for regulating bacterial physiology, including pathogenicity. Following the current discovery trends, genomic analyses will keep unearthing new CRISPR-Cas systems, sometimes even re-writing the existing rules (e.g. discovery of first known Cas9 in

nanoarchaea, (Burstein et al., 2017)). The mechanistic basis of CRISPR-based physiology is still evolving. Interestingly, the majority of spacer targets are yet to be identified, (Shmakov et al., 2017) and these target locations may hold the key to mechanisms of more CRISPR-mediated alternate functions.

Currently, Cas9, Cas1, Cas2, and Cas3 have been directly implicated in several physiological functions, suggesting potential comparable functions in other Cas proteins. So far, Cas9 has been the most divergent in function ranging from phage defense to gene regulation to directly acting as a virulence factor in *C. jejuni* (Faure et al., 2019). Future research is crucial in understanding the structure-function relations of these diverse Cas9 mechanisms. The recent finding that secretion of guide-free Cas9 by *C. jejuni* can inflict host cell DNA damage points to Cas9 mechanisms that are independent of guide RNA (Sundaresan et al., 2017; Saha et al., 2020b).

The arms race between bacteria and viruses has delivered an arsenal of anti-CRISPR proteins (Marino et al., 2020). In an interesting twist, the use of CasΦ by huge phages showed adaptation of CRISPR-Cas mechanisms to ward off virophages (Pausch et al., 2020). The fitness cost benefits of an active CRISPR system and the maintenance of degenerated CRISPR-Cas systems in several bacteria provide interesting future research avenues. CRISPR-Cas systems have proven unique because of their repurposing into powerful diagnostic, therapeutic and experimental tools. While there are several aspects such as off-target effects and promiscuous DNA damage that need to be fixed by future research (Haapaniemi et al., 2018; Wang et al., 2020), the days of personal precision genome medicine are a step closer with this powerful technology.

AUTHOR CONTRIBUTIONS

SN, HPP, LM, and RR wrote, reviewed, and edited the manuscript. All authors contributed to the article and approved the submitted version.

FUNDING

The preparation of this review article was supported by a National Science Foundation grant (grant number MCB-1716423) and by a grant from the Research Council of the University of Oklahoma Norman Campus to RR.

ACKNOWLEDGMENTS

We thank Dr. Kesavan Babu for critical discussions during the preparation of this review. We acknowledge the financial support

provided from the Office of the Vice President for Research and Partnerships and the Office of the Provost, University of Oklahoma towards the publication cost.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: <https://www.frontiersin.org/articles/10.3389/fcimb.2020.619763/full#supplementary-material>

REFERENCES

- Abudayyeh, O., Gootenberg, O. S., J., Konermann, S., Joung, J., Slaymaker, I. M., et al. (2016). C2c2 is a single-component programmable RNA-guided RNA-targeting CRISPR effector. *Science* 353, aaf5573. doi: 10.1126/science.aaf5573
- Abudayyeh, O., Gootenberg, O. S., J., Essletzbichler, P., Han, S., Joung, J., et al. (2017). RNA targeting with CRISPR-Cas13. *Nature* 550, 280–284. doi: 10.1038/nature24049
- Aklujkar, M., and Lovley, D. R. (2010). Interference with histidyl-tRNA synthetase by a CRISPR spacer sequence as a factor in the evolution of *Pelobacter carbinolicus*. *BMC Evol. Biol.* 10:230. doi: 10.1186/1471-2148-10-230
- Babu, M., Beloglazova, N., Flick, R., Graham, C., Skarina, T., Nocek, B., et al. (2011). A dual function of the CRISPR-Cas system in bacterial antiviral immunity and DNA repair. *Mol. Microbiol.* 79, 484–502. doi: 10.1111/j.1365-2958.2010.07465.x
- Barrangou, R., Fremaux, C., Deveau, H., Richards, M., Boyaval, P., Moineau, S., et al. (2007). CRISPR Provides Acquired Resistance Against Viruses in Prokaryotes. *Science* 315, 1709. doi: 10.1126/science.1138140
- Batra, R., Nelles, D. A., Pirie, E., Blue, S. M., Marina, R. J., Wang, H., et al. (2017). Elimination of Toxic Microsatellite Repeat Expansion RNA by RNA-Targeting Cas9. *Cell* 170, 899–912.e10. doi: 10.1016/j.cell.2017.07.010
- Bolotin, A., Quinquis, B., Sorokin, A., and Ehrlich, S. D. (2005). Clustered regularly interspaced short palindrome repeats (CRISPRs) have spacers of extrachromosomal origin. *Microbiology* 151, 2551–2561. doi: 10.1099/mic.0.28048-0
- Breinig, M., Schweitzer, A. Y., Herianto, A. M., Revia, S., Schaefer, L., Wendler, L., et al. (2019). Multiplexed orthogonal genome editing and transcriptional activation by Cas12a. *Nat. Methods* 16, 51–54. doi: 10.1038/s41592-018-0262-1
- Brouns, S. J. J., Jore, M. M., Lundgren, M., Westra, E. R., Slijkhuys, R. J. H., Snijders, A. P. L., et al. (2008). Small CRISPR RNAs guide antiviral defense in prokaryotes. *Science* 321, 960–964. doi: 10.1126/science.1159689
- Burstein, D., Harrington, L. B., Strutt, S. C., Probst, A. J., Anantharaman, K., Thomas, B. C., et al. (2017). New CRISPR-Cas systems from uncultivated microbes. *Nature* 542, 237–241. doi: 10.1038/nature21059
- Cameron, P., Coons, M. M., Kloppe, S. E., Lied, A. M., Smith, S. C., Vidal, B., et al. (2019). Harnessing type I CRISPR-Cas systems for genome engineering in human cells. *Nat. Biotechnol.* 37, 1471–1477. doi: 10.1038/s41587-019-0310-0
- Charpentier, E., Richter, H., van der Oost, J., and White, M. F. (2015). Biogenesis pathways of RNA guides in archaeal and bacterial CRISPR-Cas adaptive immunity. *FEMS Microbiol. Rev.* 39, 428–441. doi: 10.1093/femsre/fuv023
- Chen, J. S., Dagdas, Y. S., Kleinstiver, B. P., Welch, M. M., Sousa, A. A., Harrington, L. B., et al. (2017). Enhanced proofreading governs CRISPR-Cas9 targeting accuracy. *Nature* 550, 407–410. doi: 10.1038/nature24268
- Cho, S. W., Kim, S., Kim, J. M., and Kim, J.-S. (2013). Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease. *Nat. Biotechnol.* 31, 230–232. doi: 10.1038/nbt.2507
- Chou-Zheng, L., and Hatoum-Aslan, A. (2019). A type III-A CRISPR-Cas system employs degrading nucleases to ensure robust immunity. *eLife* 8, e45393. doi: 10.7554/eLife.45393
- Cox, D. B. T., Gootenberg, J. S., Abudayyeh, O. O., Franklin, B., Kellner, M. J., Joung, J., et al. (2017). RNA editing with CRISPR-Cas13. *Science* 358, 1019–1027. doi: 10.1126/science.aag0180
- Crowley, V. M., Catching, A., Taylor, H. N., Borges, A. L., Metcalf, J., Bondy-Denomy, J., et al. (2019). A Type IV-A CRISPR-Cas System in *Pseudomonas aeruginosa* Mediates RNA-Guided Plasmid Interference *In Vivo*. *CRISPR J.* 2, 434–440. doi: 10.1089/crispr.2019.0048
- Cui, L., Wang, X., Huang, D., Zhao, Y., Feng, J., Lu, Q., et al. (2020). CRISPR-cas3 of *Salmonella* Upregulates Bacterial Biofilm Formation and Virulence to Host Cells by Targeting Quorum-Sensing Systems. *Pathogens* 9, 53. doi: 10.3390/pathogens9010053.a6
- Deltcheva, E., Chylinski, K., Sharma, C. M., Gonzales, K., Chao, Y., Pirzada, Z. A., et al. (2011). CRISPR RNA maturation by *trans*-encoded small RNA and host factor RNase III. *Nature* 471, 602–607. doi: 10.1038/nature09886
- Dolan, A. E., Hou, Z., Xiao, Y., Gramelspacher, M. J., Heo, J., Howden, S. E., et al. (2019). Introducing a Spectrum of Long-Range Genomic Deletions in Human Embryonic Stem Cells Using Type I CRISPR-Cas. *Mol. Cell* 74, 936–950.e5. doi: 10.1016/j.molcel.2019.03.014
- East-Seletsky, A., O'Connell, M. R., Knight, S. C., Burstein, D., Cate, J. H. D., Tjian, R., et al. (2016). Two distinct RNase activities of CRISPR-C2c2 enable guide-RNA processing and RNA detection. *Nature* 538, 270–273. doi: 10.1038/nature19802
- Estrella, M. A., Kuo, F.-T., and Bailey, S. (2016). RNA-activated DNA cleavage by the Type III-B CRISPR-Cas effector complex. *Genes Dev.* 30, 460–470. doi: 10.1101/gad.273722.115
- Faure, G., Makarova, K. S., and Koonin, E. V. (2019). CRISPR-Cas: Complex Functional Networks and Multiple Roles beyond Adaptive Immunity. *J. Mol. Biol.* 431, 3–20. doi: 10.1016/j.jmb.2018.08.030
- Fonfara, I., Richter, H., Bratović, M., Le Rhun, A., and Charpentier, E. (2016). The CRISPR-associated DNA-cleaving enzyme Cpf1 also processes precursor CRISPR RNA. *Nature* 532, 517–521. doi: 10.1038/nature17945
- Gaj, T., Gersbach, C. A., and Barbas, C.F., 3. (2013). ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. *Trends Biotechnol.* 31, 397–405. doi: 10.1016/j.tibtech.2013.04.004
- Gao, N. J., Al-Bassam, M. M., Poudel, S., Wozniak, J. M., Gonzalez, D. J., Olson, J., et al. (2019). Functional and Proteomic Analysis of *Streptococcus pyogenes* Virulence Upon Loss of Its Native Cas9 Nuclease. *Front. Microbiol.* 10, 1967. doi: 10.3389/fmicb.2019.01967
- Gaudelli, N. M., Komor, A. C., Rees, H. A., Packer, M. S., Badran, A. H., Bryson, D.I., et al. (2017). Programmable base editing of A•T to G•C in genomic DNA without DNA cleavage. *Nature* 551, 464–471. doi: 10.1038/nature24644
- Gleditsch, D., Pausch, P., Müller-Esparza, H., Özcan, A., Guo, X., Bange, G., et al. (2019). PAM identification by CRISPR-Cas effector complexes: diversified mechanisms and structures. *RNA Biol.* 16, 504–517. doi: 10.1080/15476286.2018.1504546
- Goldberg, G. W., Jiang, W., Bikard, D., and Marraffini, L. A. (2014). Conditional tolerance of temperate phages via transcription-dependent CRISPR-Cas targeting. *Nature* 514, 633–637. doi: 10.1038/nature13637
- Gootenberg, J. S., Abudayyeh, O. O., Kellner, M. J., Joung, J., Collins, J. J., and Zhang, F. (2018). Multiplexed and portable nucleic acid detection platform with Cas13, Cas12a, and Csm6. *Science* 360, 439. doi: 10.1126/science.aag0179

- Gunderson, F. F., and Cianciotto, N. P. (2013). The CRISPR-Associated Gene *cas2* of *Legionella pneumophila* Is Required for Intracellular Infection of Amoebae. *mBio* 4, e00074–e00013. doi: 10.1128/mBio.00074-13
- Haapaniemi, E., Botla, S., Persson, J., Schmierer, B., and Taipale, J. (2018). CRISPR–Cas9 genome editing induces a p53-mediated DNA damage response. *Nat. Med.* 24, 927–930. doi: 10.1038/s41591-018-0049-z
- Harrington, L. B., Ma, E., Chen, J. S., Witte, I. P., Gertz, D., Paez-Espino, D., et al. (2020). A scoutRNA Is Required for Some Type V CRISPR–Cas Systems. *Mol. Cell* 79, 416–424.e5. doi: 10.1016/j.molcel.2020.06.022
- Heidrich, N., Hagmann, A., Bauriedl, S., Vogel, J., and Schoen, C. (2019). The CRISPR/Cas system in *Neisseria meningitidis* affects bacterial adhesion to human nasopharyngeal epithelial cells. *RNA Biol.* 16, 390–396. doi: 10.1080/15476286.2018.1486660
- Heussler, G. E., Cady, K. C., Koeppen, K., Bhujji, S., Stanton, B. A., and O'Toole, G. A. (2015). Clustered Regularly Interspaced Short Palindromic Repeat-Dependent, Biofilm-Specific Death of *Pseudomonas aeruginosa* Mediated by Increased Expression of Phage-Related Genes. *mBio* 6, e00129–e00115. doi: 10.1128/mBio.00129-15
- Huang, Y.-H., Su, J., Lei, Y., Brunetti, L., Gundry, M. C., Zhang, X., et al. (2017). DNA epigenome editing using CRISPR–Cas SunTag-directed DNMT3A. *Genome Biol.* 18, 176. doi: 10.1186/s13059-017-1306-z
- Huo, Y., Nam, K. H., Ding, F., Lee, H., Wu, L., Xiao, Y., et al. (2014). Structures of CRISPR Cas3 offer mechanistic insights into Cascade-activated DNA unwinding and degradation. *Nat. Struct. Mol. Biol.* 21, 771–777. doi: 10.1038/nsmb.2875
- Hur, J. K., Kim, K., Been, K. W., Baek, G., Ye, S., Hur, J. W., et al. (2016). Targeted mutagenesis in mice by electroporation of Cpf1 ribonucleoproteins. *Nat. Biotechnol.* 34, 807–808. doi: 10.1038/nbt.3596
- Ishino, Y., Shinagawa, H., Makino, K., Amemura, M., and Nakata, A. (1987). Nucleotide sequence of the *iap* gene, responsible for alkaline phosphatase isozyme conversion in *Escherichia coli*, and identification of the gene product. *J. Bacteriol.* 169, 5429. doi: 10.1128/jb.169.12.5429-5433.1987
- Jansen, R., Embden, J. D. A. v., Gaastera, W., and Schouls, L. M. (2002). Identification of genes that are associated with DNA repeats in prokaryotes. *Mol. Microbiol.* 43, 1565–1575. doi: 10.1046/j.1365-2958.2002.02839.x
- Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., and Charpentier, E. (2012). A Programmable Dual-RNA-Guided DNA Endonuclease in Adaptive Bacterial Immunity. *Science* 337, 816. doi: 10.1126/science.1225829
- Jore, M. M., Lundgren, M., van Duijn, E., Bultema, J. B., Westra, E. R., Waghmare, S. P., et al. (2011). Structural basis for CRISPR RNA-guided DNA recognition by Cascade. *Nat. Struct. Mol. Biol.* 18, 529–536. doi: 10.1038/nsmb.2019
- Joung, J., Ladha, A., Saito, M., Kim, N.-G., Woolley, A. E., Segel, M., et al. (2020). Detection of SARS-CoV-2 with SHERLOCK One-Pot Testing. *N. Engl. J. Med.* 383, 1492–1494. doi: 10.1056/NEJMc2026172
- Kazlauskienė, M., Tamulaitis, G., Kostiuk, G., Venclovas, Č., and Siksnys, V. (2016). Spatiotemporal Control of Type III-A CRISPR–Cas Immunity: Coupling DNA Degradation with the Target RNA Recognition. *Mol. Cell* 62, 295–306. doi: 10.1016/j.molcel.2016.03.024
- Kazlauskienė, M., Kostiuk, G., Venclovas, Č., Tamulaitis, G., and Siksnys, V. (2017). A cyclic oligonucleotide signaling pathway in type III CRISPR–Cas systems. *Science* 357, 605. doi: 10.1126/science.aao0100
- Kleinstiver, B. P., Pattanayak, V., Prew, M. S., Tsai, S. Q., Nguyen, N. T., Zheng, Z., et al. (2016). High-fidelity CRISPR–Cas9 nucleases with no detectable genome-wide off-target effects. *Nature* 529, 490–495. doi: 10.1038/nature16526
- Komor, A. C., Kim, Y. B., Packer, M. S., Zuris, J. A., and Liu, D. R. (2016). Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. *Nature* 533, 420–424. doi: 10.1038/nature17946
- Konermann, S., Lotfy, P., Brédau, N. J., Oki, J., Shokhirev, M. N., and Hsu, P. D. (2018). Transcriptome Engineering with RNA-Targeting Type VI-D CRISPR Effectors. *Cell* 173, 665–676.e14. doi: 10.1016/j.cell.2018.02.033
- Levy, A., Goren, M. G., Yosef, I., Auster, O., Manor, M., Amitai, G., et al. (2015). CRISPR adaptation biases explain preference for acquisition of foreign DNA. *Nature* 520, 505–510. doi: 10.1038/nature14302
- Li, Y., Pan, S., Zhang, Y., Ren, M., Feng, M., Peng, N., et al. (2015). Harnessing Type I and Type III CRISPR–Cas systems for genome editing. *Nucleic Acids Res.* 44, e34–e34. doi: 10.1093/nar/gkv1044
- Li, R., Fang, L., Tan, S., Yu, M., Li, X., He, S., et al. (2016). Type I CRISPR–Cas targets endogenous genes and regulates virulence to evade mammalian host immunity. *Cell Res.* 26, 1273–1287. doi: 10.1038/cr.2016.135
- Li, X., Wang, Y., Liu, Y., Yang, B., Wang, X., Wei, J., et al. (2018). Base editing with a Cpf1–cytidine deaminase fusion. *Nat. Biotechnol.* 36, 324–327. doi: 10.1038/nbt.4102
- Liu, T. Y., and Doudna, J. A. (2020). Chemistry of Class 1 CRISPR–Cas effectors: binding, editing, and regulation. *J. Biol. Chem.* 295, 14473–14487. doi: 10.1074/jbc.REV120.007034
- Liu, L., Li, X., Wang, J., Wang, M., Chen, P., Yin, M., et al. (2017). Two Distant Catalytic Sites Are Responsible for C2c2 RNase Activities. *Cell* 168, 121–134.e12. doi: 10.1016/j.cell.2016.12.031
- Louwen, R., Horst-Kreft, D., Boer, de, A. G., Graaf, van der, L., Knegt, de, G., Hamersma, M., et al. (2013). A novel link between *Campylobacter jejuni* bacteriophage defence, virulence and Guillain-Barré syndrome. *Eur. J. Clin. Microbiol. Infect. Dis.* 32, 207–226. doi: 10.1007/s10096-012-1733-4
- Ma, K., Cao, Q., Luo, S., Wang, Z., Liu, G., Lu, C., et al. (2018). *cas9* Enhances Bacterial Virulence by Repressing the *regR* Transcriptional Regulator in *Streptococcus agalactiae*. *Infect. Immun.* 86, e00552–e00517. doi: 10.1128/IAI.00552-17
- Maji, B., Moore, C. L., Zetsche, B., Volz, S. E., Zhang, F., Shoulders, M. D., et al. (2017). Multidimensional chemical control of CRISPR–Cas9. *Nat. Chem. Biol.* 13, 9–11. doi: 10.1038/nchembio.2224
- Makarova, K. S., Aravind, L., Grishin, N. V., Rogozin, I. B., and Koonin, E. V. (2002). A DNA repair system specific for thermophilic Archaea and bacteria predicted by genomic context analysis. *Nucleic Acids Res.* 30, 482–496. doi: 10.1093/nar/30.2.482
- Makarova, K. S., Grishin, N. V., Shabalina, S. A., Wolf, Y. I., and Koonin, E. V. (2006). A putative RNA-interference-based immune system in prokaryotes: computational analysis of the predicted enzymatic machinery, functional analogies with eukaryotic RNAi, and hypothetical mechanisms of action. *Biol. Direct* 1:7. doi: 10.1186/1745-6150-1-7
- Makarova, K. S., Wolf, Y. I., Alkhnbashi, O. S., Costa, F., Shah, S. A., and Saunders, S. J. (2015). An updated evolutionary classification of CRISPR–Cas systems. *Nat. Rev. Microbiol.* 13, 722–736. doi: 10.1038/nrmicro3569
- Makarova, K. S., Wolf, Y. I., Iranzo, J., Shmakov, S. A., Alkhnbashi, O. S., Brouns, S. J. J., et al. (2020). Evolutionary classification of CRISPR–Cas systems: a burst of class 2 and derived variants. *Nat. Rev. Microbiol.* 18, 67–83. doi: 10.1038/s41579-019-0299-x
- Marino, N. D., Pinilla-Redondo, R., Csörgő, B., and Bondy-Denomy, J. (2020). Anti-CRISPR protein applications: natural brakes for CRISPR–Cas technologies. *Nat. Methods* 17, 471–479. doi: 10.1038/s41592-020-0771-6
- Mogila, I., Kazlauskienė, M., Valinskaitė, S., Tamulaitienė, G., Tamulaitis, G., and Siksnys, V. (2019). Genetic Dissection of the Type III-A CRISPR–Cas System Csm Complex Reveals Roles of Individual Subunits. *Cell Rep.* 26, 2753–2765.e4. doi: 10.1016/j.celrep.2019.02.029
- Mojica, F. J. M., Juez, G., and Rodríguez-Valera, F. (1993). Transcription at different salinities of *Haloferax mediterranei* sequences adjacent to partially modified PstI sites. *Mol. Microbiol.* 9, 613–621. doi: 10.1111/j.1365-2958.1993.tb01721.x
- Mojica, F. J. M., Díez-Villaseñor, C., García-Martínez, J., and Soria, E. (2005). Intervening Sequences of Regularly Spaced Prokaryotic Repeats Derive from Foreign Genetic Elements. *J. Mol. Evol.* 60, 174–182. doi: 10.1007/s00239-004-0046-3
- Mosterd, C., Rousseau, G. M., and Moineau, S. (2020). A short overview of the CRISPR–Cas adaptation stage1. *Can. J. Microbiol.* 67, 1–2. doi: 10.1139/cjm-2020-0212
- Murugan, K., Babu, K., Sundaresan, R., Rajan, R., and Sashital, D. G. (2017). The Revolution Continues: Newly Discovered Systems Expand the CRISPR–Cas Toolkit. *Mol. Cell* 68, 15–25. doi: 10.1016/j.molcel.2017.09.007
- Niewoehner, O., García-Doval, C., Rostol, J. T., Berk, C., Schwede, F., Bigler, L., et al. (2017). Type III CRISPR–Cas systems produce cyclic oligoadenylate second messengers. *Nature* 548, 543–548. doi: 10.1038/nature23467
- Nihongaki, Y., Kawano, F., Nakajima, T., and Sato, M. (2015). Photoactivatable CRISPR–Cas9 for optogenetic genome editing. *Nat. Biotechnol.* 33, 755–760. doi: 10.1038/nbt.3245
- O'Connell, M. R. (2019). Molecular Mechanisms of RNA Targeting by Cas13-containing Type VI CRISPR–Cas Systems. *J. Mol. Biol.* 431, 66–87. doi: 10.1016/j.jmb.2018.06.029
- Özcan, A., Pausch, P., Linden, A., Wulf, A., Schühle, K., Heider, J., et al. (2019). Type IV CRISPR RNA processing and effector complex formation in

- Aromatoleum aromaticum*. *Nat. Microbiol.* 4, 89–96. doi: 10.1038/s41564-018-0274-8
- Paul, B., and Montoya, G. (2020). CRISPR-Cas12a: Functional overview and applications. *BioMed. J.* 43, 8–17. doi: 10.1016/j.bj.2019.10.005
- Pausch, P., Al-Shayeb, B., Bisom-Rapp, E., Tsuchida, C. A., Li, Z., Cress, B. F., et al. (2020). CRISPR-CasΦ from huge phages is a hypercompact genome editor. *Science* 369, 333. doi: 10.1126/science.abb1400
- Perez-Pinera, P., Kocak, D. D., Vockley, C. M., Adler, A. F., Kabadi, A. M., Polstein, L. R., et al. (2013). RNA-guided gene activation by CRISPR-Cas9-based transcription factors. *Nat. Methods* 10, 973–976. doi: 10.1038/nmeth.2600
- Pickar-Oliver, A., and Gersbach, C. A. (2019). The next generation of CRISPR-Cas technologies and applications. *Nat. Rev. Mol. Cell Biol.* 20, 490–507. doi: 10.1038/s41580-019-0131-5
- Pinilla-Redondo, R., Mayo-Muñoz, D., Russel, J., Garrett, R. A., Randau, L., Sørensen, S. J., et al. (2020). Type IV CRISPR-Cas systems are highly diverse and involved in competition between plasmids. *Nucleic Acids Res.* 48, 2000–2012. doi: 10.1093/nar/gkz1197
- Qi, L. S., Larson, M. H., Gilbert, L. A., Doudna, J. A., Weissman, J. S., Arkin, A. P., et al. (2013). Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression. *Cell* 152, 1173–1183. doi: 10.1016/j.cell.2013.02.022
- Rath, D., Amlinger, L., Hoekzema, M., Devulapally, P. R., and Lundgren, M. (2014). Efficient programmable gene silencing by Cascade. *Nucleic Acids Res.* 43, 237–246. doi: 10.1093/nar/gku1257
- Ratner, H. K., Escalera-Maurer, A., Le Rhun, A., Jaggaravaru, S., Wozniak, J. E., Crispell, E. K., et al. (2019). Catalytically Active Cas9 Mediates Transcriptional Interference to Facilitate Bacterial Virulence. *Mol. Cell* 75, 498–510.e5. doi: 10.1016/j.molcel.2019.05.029
- Saha, C., Horst-Kreft, D., Kross, I., van der Spek, P. J., Louwen, R., and van Baaren, P. (2020a). *Campylobacter jejuni* Cas9 Modulates the Transcriptome in Caco-2 Intestinal Epithelial Cells. *Genes* 11, 1193. doi: 10.3390/genes11101193
- Saha, C., Mohanraju, P., Stubbs, A., Dugar, G., Hoogstrate, Y., Kremers, G.-J., et al. (2020b). Guide-free Cas9 from pathogenic *Campylobacter jejuni* bacteria causes severe damage to DNA. *Sci. Adv.* 6, eaaz4849. doi: 10.1126/sciadv.aaz4849
- Samai, P., Pyenson, N., Jiang, W., Goldberg, G. W., Hatoum-Aslan, A., and Marraffini, L. A. (2015). Co-transcriptional DNA and RNA Cleavage during Type III CRISPR-Cas Immunity. *Cell* 161, 1164–1174. doi: 10.1016/j.cell.2015.04.027
- Sampson, T. R., Saroj, S. D., Llewellyn, A. C., Tzeng, Y.-L., and Weiss, D. S. (2013). A CRISPR/Cas system mediates bacterial innate immune evasion and virulence. *Nature* 497, 254–257. doi: 10.1038/nature12048
- Sampson, T. R., and Weiss, D. S. (2013). Degeneration of a CRISPR/Cas system and its regulatory target during the evolution of a pathogen. *RNA Biol.* 10, 1618–1622. doi: 10.1161/rna.26423
- Sarkar, P., and Sumby, P. (2017). Regulatory gene mutation: a driving force behind group A Streptococcus strain- and serotype-specific variation. *Mol. Microbiol.* 103, 576–589. doi: 10.1111/mmi.13584
- Shabbir, M. A. B., Tang, Y., Xu, Z., Lin, M., Cheng, G., Dai, M., et al. (2018). The Involvement of the *Cas9* Gene in Virulence of *Campylobacter jejuni*. *Front. Cell Infect. Microbiol.* 8, 285. doi: 10.3389/fcimb.2018.00285
- Shmakov, S. A., Sitnik, V., Makarova, K. S., Wolf, Y. I., Severinov, K. V., and Koonin, E. V. (2017). The CRISPR Spacer Space Is Dominated by Sequences from Species-Specific Mobilomes. *mBio* 8, e01397–e01317. doi: 10.1128/mBio.01397-17
- Silas, S., Mohr, G., Sidote, D. J., Markham, L. M., Sanchez-Amat, A., Bhaya, D., et al. (2016). Direct CRISPR spacer acquisition from RNA by a natural reverse transcriptase–Cas1 fusion protein. *Science* 351, aad4234. doi: 10.1126/science.aad4234
- Sinkunas, T., Gasiunas, G., Fremaux, C., Barrangou, R., Horvath, P., and Siksnys, V. (2011). Cas3 is a single-stranded DNA nuclease and ATP-dependent helicase in the CRISPR/Cas immune system. *EMBO J.* 30, 1335–1342. doi: 10.1038/emboj.2011.41
- Slaymaker, I. M., Gao, L., Zetsche, B., Scott, D. A., Yan, W. X., and Zhang, F. (2016). Rationally engineered Cas9 nucleases with improved specificity. *Science* 351, 84. doi: 10.1126/science.aad5227
- Smith, E. E., Buckley, D. G., Wu, Z., Saenphimmachak, C., Hoffman, L. R., D'Argenio, D. A., et al. (2006). Genetic adaptation by *Pseudomonas aeruginosa* to the airways of cystic fibrosis patients. *Proc. Natl. Acad. Sci. U.S.A.* 103, 8487. doi: 10.1073/pnas.0602138103
- Spencer, B. L., Deng, L., Patras, K. A., Burcham, Z. M., Sanches, G. F., Nagao, P. E., et al. (2019). Cas9 Contributes to Group B Streptococcal Colonization and Disease. *Front. Microbiol.* 10, 1930. doi: 10.3389/fmicb.2019.01930
- Staals, R. H. J., Agari, Y., Maki-Yonekura, S., Zhu, Y., Taylor, D. W., van Duijn, E., et al. (2013). Structure and Activity of the RNA-Targeting Type III-B CRISPR-Cas Complex of *Thermus thermophilus*. *Mol. Cell* 52, 135–145. doi: 10.1016/j.molcel.2013.09.013
- Staals, R. H. J., Zhu, Y., Taylor, D. W., Kornfeld, J. E., Sharma, K., Barendregt, A., et al. (2014). RNA Targeting by the Type III-A CRISPR-Cas Csm Complex of *Thermus thermophilus*. *Mol. Cell* 56, 518–530. doi: 10.1016/j.molcel.2014.10.005
- Sternberg, S. H., Richter, H., Charpentier, E., and Qimron, U. (2016). Adaptation in CRISPR-Cas Systems. *Mol. Cell* 61, 797–808. doi: 10.1016/j.molcel.2016.01.030
- Strutt, S. C., Torrez, R. M., Kaya, E., Negrete, O. A., and Doudna, J. A. (2018). RNA-dependent RNA targeting by CRISPR-Cas9. *Elife* 7, e32724. doi: 10.7554/eLife.32724
- Sundaresan, R., Parameshwaran, H. P., Yagesha, S. D., Keilbarth, M. W., and Rajan, R. (2017). RNA-Independent DNA Cleavage Activities of Cas9 and Cas12a. *Cell Rep.* 21, 3728–3739. doi: 10.1016/j.celrep.2017.11.100
- Tamulaitis, G., Venclovas, Č., and Siksnys, V. (2017). Type III CRISPR-Cas Immunity: Major Differences Brushed Aside. *Trends Microbiol.* 25, 49–61. doi: 10.1016/j.tim.2016.09.012
- Tang, B., Gong, T., Zhou, X., Lu, M., Zeng, J., Peng, X., et al. (2019). Deletion of *cas3* gene in *Streptococcus mutans* affects biofilm formation and increases fluoride sensitivity. *Arch. Oral Biol.* 99, 190–197. doi: 10.1016/j.archoralbio.2019.01.016
- Taylor, D. W., Zhu, Y., Staals, R. H. J., Kornfeld, J. E., Shinkai, A., van der Oost, J., et al. (2015). Structures of the CRISPR-Cmr complex reveal mode of RNA target positioning. *Science* 348, 581. doi: 10.1126/science.aaa4535
- Taylor, H. N., Warner, E. E., Armbrust, M. J., Crowley, V. M., Olsen, K. J., and Jackson, R. N. (2019). Structural basis of Type IV CRISPR RNA biogenesis by a Cas6 endoribonuclease. *RNA Biol.* 16, 1438–1447. doi: 10.1080/15476286.2019.1634965
- Vega, L. A., Malke, H., and McIver, K. S. (2016). *Virulence-Related Transcriptional Regulators of Streptococcus pyogenes* (Oklahoma City (OK: University of Oklahoma Health Sciences Center). Available at: <http://europepmc.org/abstract/MED/26866215>.
- Vercos, R. B., Chang, J. T., Dy, R. L., Taylor, C., Gristwood, T., Clulow, J. S., et al. (2013). Cytotoxic chromosomal targeting by CRISPR/Cas systems can reshape bacterial genomes and expel or remodel pathogenicity islands. *PLoS Genet.* 9, e1003454–e1003454. doi: 10.1371/journal.pgen.1003454
- Viswanathan, P., Murphy, K., Julien, B., Garza, A. G., and Kroos, L. (2007). Regulation of *dev*, an Operon That Includes Genes Essential for *Myxococcus xanthus* Development and CRISPR-Associated Genes and Repeats. *J. Bacteriol.* 189, 3738. doi: 10.1128/JB.00187-07
- Wallace, R. A., Black, W. P., Yang, X., and Yang, Z. (2014). A CRISPR with Roles in *Myxococcus xanthus* Development and Exopolysaccharide Production. *J. Bacteriol.* 196, 4036–4043. doi: 10.1128/JB.02035-14
- Wang, Y., Yin, X., Zhou, Z., Hu, S., Li, S., Liu, M., et al. (2019). Cas9 regulated gene expression and pathogenicity in *Riemerella anatipestifer*. *Microb. Pathog.* 136, 103706. doi: 10.1016/j.micpath.2019.103706
- Wang, Y., Wang, M., Zheng, T., Hou, Y., Zhang, P., Tang, T., et al. (2020). Specificity profiling of CRISPR system reveals greatly enhanced off-target gene editing. *Sci. Rep.* 10, 2269. doi: 10.1038/s41598-020-58627-x
- Watson, B. N. J., Staals, R. H. J., and Fineran, P. C. (2018). CRISPR-Cas-Mediated Phage Resistance Enhances Horizontal Gene Transfer by Transduction. *mBio* 9, e02406–e02417. doi: 10.1128/mBio.02406-17
- Wilson, T. E., Topper, L. M., and Palmbo, P. L. (2003). Non-homologous end-joining: bacteria join the chromosome breakdance. *Trends Biochem. Sci.* 28, 62–66. doi: 10.1016/S0968-0004(03)00005-7
- Wimmer, F., and Beisel, C. L. (2020). CRISPR-Cas Systems and the Paradox of Self-Targeting Spacers. *Front. Microbiol.* 10, 3078. doi: 10.3389/fmicb.2019.03078
- Xu, X., and Qi, L. S. (2019). A CRISPR-dCas Tool for Genetic Engineering and Synthetic Biology. *J. Mol. Biol.* 431, 34–47. doi: 10.1016/j.jmb.2018.06.037

- Yan, M.-Y., Yan, H.-Q., Ren, G.-X., Zhao, J.-P., Guo, X.-P., and Sun, Y.-C. (2017). CRISPR-Cas12a-Assisted Recombineering in Bacteria. *Appl. Environ. Microbiol.* 83, e00947–e00917. doi: 10.1128/AEM.00947-17
- Yan, W. X., Hunnewell, P., Alfonse, L. E., Carte, J. M., Keston-Smith, E., Sothilsvam, S., et al. (2019). Functionally diverse type V CRISPR-Cas systems. *Science* 363, 88. doi: 10.1126/science.aav7271
- You, L., Ma, J., Wang, J., Artamonova, D., Wang, M., Liu, L., et al. (2019). Structure Studies of the CRISPR-Csm Complex Reveal Mechanism of Co-transcriptional Interference. *Cell* 176, 239–253.e16. doi: 10.1016/j.cell.2018.10.052
- Young, J. K., Gasior, S. L., Jones, S., Wang, L., Navarro, P., Vickroy, B., et al. (2019). The repurposing of type I-E CRISPR-Cascade for gene activation in plants. *Commun. Biol.* 2, 383. doi: 10.1038/s42003-019-0637-6
- Zebec, Z., Manica, A., Zhang, J., White, M. F., and Schleper, C. (2014). CRISPR-mediated targeted mRNA degradation in the archaeon *Sulfolobus solfataricus*. *Nucleic Acids Res.* 42, 5280–5288. doi: 10.1093/nar/gku161
- Zetsche, B., Gootenberg, J. S., Abudayyeh, O. O., Slaymaker, I. M., Makarova, K. S., Essletzbichler, P., et al. (2015). Cpf1 is a single RNA-guided endonuclease of a class 2 CRISPR-Cas system. *Cell* 163, 759–771. doi: 10.1016/j.cell.2015.09.038
- Zhang, Y., Heidrich, N., Ampattu, B. J., Gunderson, C. W., Seifert, H. S., Schoen, C., et al. (2013). Processing-Independent CRISPR RNAs Limit Natural Transformation in *Neisseria meningitidis*. *Mol. Cell* 50, 488–503. doi: 10.1016/j.molcel.2013.05.001
- Zhang, X., Wang, J., Cheng, Q., Zheng, X., Zhao, G., and Wang, J. (2017). Multiplex gene regulation by CRISPR-ddCpf1. *Cell Discov.* 3, 17018. doi: 10.1038/celldisc.2017.18

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Newsom, Parameshwaran, Martin and Rajan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.